A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database.

MLA

Tang, Linlin, et al. “A Pharmacovigilance Study of Adverse Event Profiles and Haemorrhagic Safety of Bevacizumab Based on the FAERS Database.” Expert Opinion on Drug Safety, vol. 23, no. 2, Feb. 2024, pp. 213–20. EBSCOhost, https://doi.org/10.1080/14740338.2023.2248876.

APA

Tang, L., Ding, C., Li, H., Yin, G., Zhang, H., Liu, W. S., Ji, Y., & Li, H. (2024). A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database. Expert Opinion on Drug Safety, 23(2), 213–220. https://doi.org/10.1080/14740338.2023.2248876

Chicago

Tang, Linlin, Chuanhua Ding, Hongying Li, Guoqiang Yin, Haixia Zhang, Wen Shan Liu, Yinghui Ji, and Hui Li. 2024. “A Pharmacovigilance Study of Adverse Event Profiles and Haemorrhagic Safety of Bevacizumab Based on the FAERS Database.” Expert Opinion on Drug Safety 23 (2): 213–20. doi:10.1080/14740338.2023.2248876.